Published: October 2021
Given that conventional therapies have been unable to exhibit significant efficacy in the treatment of RAS mutated cancers, novel drugs, specifically targeting the RAS gene, have emerged as a promising alternative, supported by extensive research
Growing research activity in the RAS targeting domain has resulted in a surge in the interest of biopharmaceutical developers in this rapidly evolving sector. These therapies are being developed against specific oncogenic RAS mutations that are believed to be responsible for close to 30% of the overall human cancers. Moreover, the first and only approved RAS targeted therapy, named LUMAKRASTM, has provided a boost to this market, by providing a treatment for a previously deemed undruggable target.
To order this 140+ page report, which features 95+ figures, please visit https://www.rootsanalysis.com/reports/ras-targeting-therapies-market.html
More than 155 drug candidates targeting the RAS gene are currently being investigated
Over 70% of the therapies are being evaluated across preclinical and clinical stages, either as monotherapies or in combination with other products. Majority of the RAS targeting therapies (79%) are designed for administration via the oral route.
22,000+ patients have been enrolled in over 120 clinical trials, worldwide
Clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of 5%, in the past three years. Of the total number of trials, close to 25% of the studies have already been completed, while 60% are active and still recruiting patients.
Close to 300 articles focused on RAS mutated colorectal cancer have been published
Several industry, as well as non-industry, players engaged in this domain are undertaking numerous initiatives to identify and develop novel RAS targeting therapies. Majority of the authors affiliated to deemed universities have published articles focused on KRAS (80%), in last one year.
Partnership activity has grown at an annualized rate of nearly 10%, between 2017 and 2020
Maximum number of partnerships were observed to be inked in 2019, indicating a recent rise in the interest of stakeholders in this domain. Majority of the deals were reported to be product licensing agreements, representing over 30% of the total number of instances.
Over USD 1,500 million has been invested by both private and public investors, since 2016
Of the total, close to USD 600 million was raised through venture capital financing, representing around 40% of the overall share. On the other hand, over 5 instances of IPOs / secondary offerings were reported, wherein players collectively raised more than USD 775 million in financing.
North America and Europe anticipated to capture over 90% of market share by 2031
Growth in this domain is anticipated to be primarily driven by encouraging clinical trial results and the growing demand for targeted therapeutic modalities. It is worth mentioning that small molecules currently represent a significant share of the overall market, and this trend is unlikely to change in the foreseen future.
To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/ras-targeting-therapies-market.html
The financial opportunity associated with the RAS targeting therapies market has been analyzed across the following segments:
The research includes detailed profiles of 85+ drugs being developed by key players (listed below); each profile further features an overview of the developer, details related to its financials (if available), recent developments, and an informed future outlook.
For additional details, please visit
https://www.rootsanalysis.com/reports/ras-targeting-therapies-market.html or email email@example.com
You may also be interested in the following titles:
1. Squamous Non-Small Cell Lung Cancer Market, 2021-2031
2. Novel T-Cell Immunotherapies Market, 2021-2030
3. HER2 Targeting Therapies Market, 2021-2030
+1 (415) 800 3415
+44 (122) 391 1091
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry
SUBSCRIBE TO INDUSTRY UPDATES